Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus fermentum TSF331 + lactobacillus reuteri TSR332 + lactobacillus plantarum TSP05
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A **combination probiotic live biotherapeutic** product containing three specific strains: Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05, developed for the **improvement of liver function** and **management of serum uric acid (UA) levels**, particularly in individuals with metabolic-associated fatty liver disease (MAFLD) and hyperuricemia. These strains, isolated from healthy human gut and traditional fermented foods, demonstrate high antioxidant capacity, reduce oxidative stress and inflammatory responses in preclinical models, and promote commensal gut microbiota while reducing pathobiont populations. Their mechanism includes **purine nucleoside assimilation without generating excess UA** as well as **enhanced excretion of UA in the gut**. Clinical trials have shown significant reductions in AST, ALT, and UA without adverse effects, supporting their safety and efficacy for liver health and metabolic balance[1][3].
- Brand names
- PRONULIFE LvUCare
- Other names
- lactobacillus fermentum TSF331 + lactobacillus reuteri TSR332 + lactobacillus plantarum TSP05
Beyond the preview
Go deeper on lactobacillus fermentum TSF331 + lactobacillus reuteri TSR332 + lactobacillus plantarum TSP05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus fermentum TSF331 + lactobacillus reuteri TSR332 + lactobacillus plantarum TSP05.